Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

Background: Although lenvatinib has become the standard therapy for hepatocellular carcinoma (HCC), the high incidence rate of adverse events (AEs) is an issue. This study aimed to clarify the AEs of lenvatinib and the therapeutic impact of five days-on/two days-off administration (i.e., weekends-of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Iwamoto, Hideki, Suzuki, Hiroyuki, Shimose, Shigeo, Niizeki, Takashi, Nakano, Masahito, Shirono, Tomotake, Okamura, Shusuke, Noda, Yu, Kamachi, Naoki, Nakamura, Toru, Masuda, Atsutaka, Sakaue, Takahiko, Tanaka, Toshimitsu, Nakano, Dan, Sakai, Miwa, Yamaguchi, Taizo, Kuromatsu, Ryoko, Koga, Hironori, Torimura, Takuji
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226076/
https://ncbi.nlm.nih.gov/pubmed/32325921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados